President & CEO, Emergent BioSolutions Inc.

Mr. Abdun-Nabi is the President and Chief Executive Officer of Emergent BioSolutions, a NYSE listed global biopharmaceutical company  that pursues the development and commercialization of innovative products to prevent or treat infectious diseases, cancers, and autoimmune disorders. He has held this position since April 2012.  Prior to that, he served as President and Chief Operating Officer (March 2007 to April 2012), as Senior Vice President Corporate Affairs and General Counsel (December 2004 to April 2007), and as Vice President and General Counsel (May 2004 to December 2004) of the company.


Michael Baader

General Counsel, Greenspring Associates

Mike joined Greenspring Associates in 2014 as the Firm’s General Counsel. Previously, Mike was the Partner-in-Charge of Venable LLP’s Baltimore Office. Historically, Mike’s practice centered on all aspects of corporate planning and business advisory services with a special focus on private equity and venture capital. He has regularly been recognized as one of the region’s top business lawyers in the Baltimore Business Journal, Baltimore Smart CEO, Baltimore Magazine, Best Lawyers in America and Chambers USA. He is Martindale-Hubbell AV Peer Rated. In 2012 and 2013, Mr. Baader was recognized by Super Lawyers as one of the “Top 100 Lawyers” in Maryland. Mike holds a J.D. with honors from The College of William and Mary and is a graduate of the University of Virginia.

rbendisPresident & CEO, BioHealth Innovation, Inc.

Mr. Bendis is an entrepreneur, corporate executive, venture capitalist, investment banker, innovation and technology-based economic development leader, international speaker and consultant in the technology and healthcare industries. He currently serves as the founding President and CEO of Innovation America (IA), a national public-private partnership focused on accelerating the growth of innovation economy in America. As one of the most recognized experts in the field of innovation economy, Mr. Bendis has served on numerous distinguished boards and task forces including the White House U.S. Innovation Partnership Advisory Task Force, the Small Business Innovation Research Committee, the National Association of State Venture Funds board; State Science and Technology Institute, and the Ernst and Young Entrepreneurial Institute as a national/regional Judge.

Mr. Bendis has provided global consulting services to over 16 countries and 22 states, several cities and regions, along with international organizations including the United Nations, NATO, UK Trade and Industry, European Commission, French Embassy, the German Marshall Fund, The Canadian Consulate, METI, AKEA, the International Science Parks and Innovation Expert Group and other global entities. Mr. Bendis is a frequent consultant and speaker to 16 International innovation based economic development organizations, as well as over 20 states, regions and cities throughout the U.S. He was voted one of the Top 5 Speakers on innovation economy in 2012.

Group Vice President, Healthcare Banking, M&T BankChristopher Callaghan

Mr. Callaghan manages M&T’s Healthcare Banking Group, providing sales advisory, credit oversight and industry training to the team. Christopher joined M&T Bank in 1994. He has held several positions in the Corporate Banking and Institutional Investment Management Divisions at M&T, including 15 years in the Healthcare Banking Group. M&T’s Healthcare Banking Group is a Specialized Industry Group that provides Commercial Lending, Investment Banking, Treasury Management and other Financial Services to Health Systems, Hospitals, Skill Nursing Facilities and Senior Living Communities. Christopher received a Bachelor of Arts degree in Economics from Saint Michael’s College in Winooski, Vermont and a Master’s of Science in Finance from The Johns Hopkins University. He is a member of the Board of Directors of Evergreen Healthcare Cooperative, the Board of Visitors of the University of Maryland School of Nursing and is active in several healthcare industry groups.

President and CEO, Noble Life Sciences

kenneth carter

Dr. Carter has been involved in the formation and early stage development of several biotechnology companies as a co-founder, consultant or member of the board of directors. He co-founded Avalon Pharmaceuticals, Inc. in January 1999 and served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During this time, Avalon developed a unique biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established drug discovery programs in colon, breast, pancreatic and hematological cancers; and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune.

Prior to that, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he worked for several years and played a role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter has served on the boards of directors for multiple biotechnology industry organizations including the Maryland Health Care Product Development Corporation and the National BIO Industry Organization. He also served recently as a special advisor to the Maryland Governor's Life Sciences Advisory Board and is on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he also holds an adjunct faculty appointment.


President, Johns Hopkins University

Ronald J. Daniels became the 14th president of The Johns Hopkins University in March 2009. A law and economics scholar, he holds an appointment as professor in the Department of Political Science at Johns Hopkins. Prior to his appointment, he served as provost of the University of Pennsylvania, and dean and James M. Tory Professor of Law at the University of Toronto Faculty of Law. Daniels' own research focuses on the intersections of law, economics, development and public policy, in such areas as corporate and securities law, social and economic regulation and the role of law and legal institutions in promoting third world development. He is the author or co-author of dozens of scholarly articles, and the author or editor of seven books.

Daniels currently sits on the boards of the East Baltimore Development Inc., the Baltimore Community Foundation, the Goldseker Foundation, the Maryland Chamber of Commerce, the Governor's International Advisory Council, and the Asia Pacific Rim Universities World Institute. He is serving as a member of the Association of American Universities-Association of Leading Russian Universities steering committee to help guide collaborations between member universities. He is also engaged in the Center for Health Policy and Healthcare Transformation at Johns Hopkins. In 2009, he was elected a fellow of the American Academy of Arts and Sciences.

Judy DunnVice President, Global Head of Clinical Development, Roche

Dr. Judith Dunn is the Vice President, Global Head of Clinical Development at Hoffmann-La Roche’s Pharmaceutical Research and Early Development group. She is also leading the Roche Innovation Center in New York located in the Alexandria Center for Life Science in Manhattan. Prior to joining Roche, Judy held positions in both the research and commercial divisions of Pfizer, led clinical programs in psychiatry at Sepracor, and served as Vice President of Clinical Research at Flexion, a start-up biotech company. Judy has a keen interested in methodology, and has published several papers on the topic. In addition, she is a founding member and Chair of the Scientific Program Committee for the CNS Summit, an organization focused on delivering new treatments to patients suffering from brain disorders through stakeholder collaboration. Judy attended Wesleyan University and the University of Rochester, where she obtained undergraduate and graduate degrees in Neurobiology. She has been the recipient of a research fellowship in neuropharmacology from the Center for Brain Research at Strong Memorial Hospital and a Postdoctoral Fellowship in Clinical Research from Pfizer.

jens eckstein

President, SR One

Dr. Eckstein is the President of SR One which is the corporate venture capital arm of GlaxoSmithKline. He came to GlaxoSmithKline from TVM Capital where he was a Venture Partner, Entrepreneur-in Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, he was a General Partner in TVMs Boston life sciences practice where he focused on earlier-stage investments. He was a member of the Board of Directors for CoNCERT Pharmaceuticals, Enanta Pharmaceuticals, SelectX Pharmaceuticals, Rapid Micro Biosystems, Anchor Therapeutics, and an Advisor to Sirtris Pharmaceuticals.


David M. Gillece

Regional Managing Principal, Cassidy Turley

David Gillece oversees Cassidy Turley’s offices in Baltimore, MD. He also serves on the Board of Cassidy Turley. David has a strong background in Corporate Services, having served in senior positions with major accounts. He maintains a strong Advisory/ Tenant Representation practice. Major clients have included Legg Mason, Under Armour, Travelers, The Johns Hopkins University and RTKL.

David chairs Cassidy Turley’s Life Science practice group. He served as Chairman of the Board of the State of Maryland’s Enterprise Investment Fund, an early stage equity fund focused on young technology companies. He has also served as consultant to the University of Maryland Baltimore County in the development of its university research park and on the listing team at the Johns Hopkins and University of Maryland bioparks.

Prior to joining Cassidy Turley, Mr. Gillece served as President and CEO of the Baltimore Development Corporation, Baltimore City’s economic development agency. 

rick iveyWW Vice President Research & Development, BD Diagnostics

Rick is the overall R&D Leader for the Diagnostic Systems Research and Development Function. Rick works closely with the business leaders to drive new growth opportunities via technology and product development, collaborative partnerships, technology functional excellence, platform management, technology planning, and hiring of talent to meet our strategic goals. Diagnostic Systems comprises several BD Market Segment Areas including Molecular Diagnostics (BD Max and BD Viper), Infection Prevention and Management (includes Microbiology, POC and Industrial platforms), and Women's Health. The R&D team is comprised of a strong Systems Engineering function with equally strong Microbiology, Molecular, Chemistry, Immuno and Cytology teams located in multiple sites in North America. Rick has received multiple patents in the field of rapid Sepsis Detection, a strong area of personal interest. Rick received his B.S. in Mechanical Engineering from Virginia Tech and a Masters in Engineering Science and Administration from The George Washington University.



Chancellor, University System of Maryland

William E. Kirwan, Chancellor of the University System of Maryland since August 1, 2002, is a nationally recognized authority on critical issues shaping the higher education landscape. He served as President of Ohio State University for four years (1998-2002) and President of the University of Maryland, College Park for 10 years (1988-1998). Prior to his presidency, he was a member of the University of Maryland faculty for 24 years.

Currently, Dr. Kirwan chairs the National Research Council Board of Higher Education and Workforce, the College Board Advocacy & Policy Center Advisory Committee, and co-chairs the Knight Commission on Intercollegiate Athletics. He also is chairman of the Business-Higher Education Forum. In Maryland, Dr. Kirwan co-chairs the Governor's P-20 STEM Task Force and is a member of the Governor's International Advisory Board and the Maryland Economic Development Commission.

In 2007, Dr. Kirwan is a recipient of numerous honors and awards including the 16th recipient of the Maryland House of Delegates Speakers' Medallion and the Maryland Senate's First Citizen Award in 1998, and the 2009 Carnegie Corporation Leadership Award, which included a $500,000 grant to fund USM academic priorities. Dr. Kirwan received his bachelor's degree in mathematics from the University of Kentucky and his master's and doctoral degrees in mathematics from Rutgers, The State University of New Jersey, in 1962 and 1964 respectively.

dave-lemusCEO, Sigma-Tau Pharmaceuticals, Inc.

Dave Lemus heads Sigma Tau Pharmaceuticals activities in North America, based in Gaithersburg, MD, which conducts the R&D, global manufacturing and sales/ commercialization within the Americas, of the company’s Rx (rare disease) and OTC therapeutics portfolio. Dave also currently serves as a non-executive board member of various European and North American companies, including board chair of Proteros GmbH, a leading structural biology focused company co- founded by Nobel prize-winner Dr. Robert Huber. Additionally he serves as a non-executive board member of Medigene AG, a publically listed biotechnology company in Germany, as well as Axela Inc., a private diagnostics company based in Toronto, Canada.

joel-marcusCEO & Founder, Alexandria Real Estate Equities, Inc.

Joel S. Marcus is the Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), the largest and leading REIT uniquely focused on collaborative science and technology campuses in urban innovation clusters. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with a business plan and $19 million of seed capital, and has led its growth into a publicly traded, investment-grade REIT with a total market capitalization of approximately $9 billion and dominant market presence in leading AAA locations, including Greater Boston, the San Francisco Bay Area, New York City, Seattle, San Diego, Maryland, and Research Triangle Park. Mr. Marcus founded and leads Alexandria Venture Investments, the Company’s strategic venture arm, which has made over 200 investments in biopharmaceuticals, diagnostics, research tools, technology platforms, medical devices, digital health, and other cutting-edge technologies.

dougliuSenior Vice President of Global Operations, QIAGEN

Douglas Liu has a twenty five year record of international success in operations, strategic planning and Research & Development in molecular diagnostics, immunodiagnostics and other healthcare market segments. 

Douglas Liu is the Senior Vice President of Global Operations, a member of the Executive Committee and the senior QIAGEN Executive assigned in North America.  As the head of Global Operations, Douglas manages Manufacturing, Quality Control, Quality Assurance, Regulatory Affairs, and Supply Chain worldwide.   He is also the Chairman of the America Management Council at the QIAGEN Germantown/Gaithersburg/Frederick office where he provides leadership and guidance to all of the US subsidiaries, projects, and employees.  Under his management and commitment to success, QIAGEN North America has achieved and contributed to multiple successful projects and its growth, including the Germantown campus expansion.

Before joining QIAGEN, Douglas worked for Bayer Healthcare as Head of Operations for nucleic acid diagnostics in the US, and in strategic planning and consulting at Bayer AG in Leverkusen.  Prior to these positions, Douglas also worked at Abbott Labs and Chiron Diagnostics.

Douglas received his MBA from Boston University and his Bachelor Science degree from University of Illinois, Urbana

Douglas lived and worked in Germany for five years.  In 2007, Douglas and his family relocated back to United States. He has served in several local advisory boards since returning to the US including the Governor International Advisory Council & the MD Bio Tech Council of Maryland.

beth-meagherDirector, Deloitte Consulting LLP

Ms. Meagher has over 19 years of experience leading strategic initiatives for clients in commercial, government, and non-profit sectors. Currently, she is leading Deloitte’s Federal Strategy Practice with over 90 consultants and she started and leads Deloitte’s Translational Science Team with over 35 practitioners and is the Federal Life Sciences Market Lead and Federal Health Analytics Lead. She is leading efforts to assist clients in analytics efforts, growth strategies, public private partnerships, strategic planning, program evaluation, stakeholder management, change management, executive leadership, and communication strategies. Ms. Meagher is an expert at Go To Market strategy development, routinely developing high performing teams that outperform the market. She has C-suite relationships across the Federal, Commercial, and Non Profit markets. She holds a MA in Organization Effectiveness and a BA in Communication Studies and Entrepreneurial Studies.

charles-mortonPartner, Venable

Chuck Morton, repeatedly ranked as one of the top M&A lawyers in the country, co-chairs Venable's Corporate Practice Group, splitting his time between Venable's Washington and Baltimore offices. He has a national practice, solving complex problems faced by lenders, investors, and entrepreneurs as they create, build, and buy or sell businesses. He routinely advises on mergers and acquisitions and financings, including every flavor of equity investment. He regularly acts on behalf of private equity groups and banks.


General Partner, New Enterprise Associates, NEA

David M. Mott joined NEA in September 2008 as a General Partner focused on biopharmaceutical investments. Prior to joining NEA, he was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Dave joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and Chief Executive Officer as the company grew from a venture-backed startup (founded in 1988) into one of the top five biotechnology companies in the world. Ultimately, he initiated and executed the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. In 2002, Dave founded MedImmune Ventures and chaired its investment committee through his departure from MedImmune. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees.

Prior to joining MedImmune, Dave was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc. At Smith Barney, his activities included public and private equity and debt financings as well as merger and acquisition work for biotechnology, healthcare services, and medical product and device companies. Dave is currently Chairman of 3-V Biosciences, TESARO, and Zyngenia and is a director of Ardelyx, Epizyme, and Omthera. He also serves on the Governing Board of St. Albans School.

tom-sadowskiPresident and CEO, Economic Alliance of Greater Baltimore

The Economic Alliance is a partnership of business, government and higher education leaders marketing Greater Baltimore as a world-class region in which to work, learn, live and invest.

Tom joined the Alliance in Jan 2006 to manage the Region's response to the 2005 DOD Base Realignment and Closure (BRAC) initiative. Since, he has led strategic marketing efforts reaching more than 20,000 defense/IT, cyber and bio-health industry execs; executed sales missions to Austin, NYC, Palo Alto and San Francisco; increased business retention, development and public/private partnership activity; and published a new series of regional, industry-specific market reports. His work has also helped foster new regional and state-wide initiatives in the areas of tech transfer, commercialization and entrepreneurship, working with Johns Hopkins, the University of Maryland and federal customers such as NIH, APG and US Cyber Command.

In his 24 year career, he led the '05 BRAC win for Aberdeen Proving Ground; brokered major development and HQ/campus projects for Battelle, Bank of America, SafeNet, T. Rowe Price and the US Centers for Medicare and Medicaid Services (CMS). His clients to date have included: ADP, Booz Allen, CACI, Clorox, FLIR, Millennial Media, Morgan Stanley, Transamerica and Under Armour to name a few.

Overall, his projects have exceeded $10 billion in value, resulting in approximately 60,000 jobs. His efforts have been recognized by local media, most recently named as an "Influential Marylander" and one of "Maryland Most Admired CEOs."

He is a proud husband, father of four boys and graduate of UMBC and Leadership Maryland. A 10+ year cancer survivor, Tom is also an advocate for enhanced awareness, research and family services.


Vice President, Head of Partnering and Strategy, MedImmune


Dr. Seeto rejoined the MedImmune Leadership Team (MLT) in 2013 to lead the Partnering and Strategy Group. He is responsible for MedImmune's Business Development and Strategy teams that will deliver our external partnership strategy including academic collaborations, licensing of innovative assets and technologies and government alliances/partnerships and for all therapy area strategies. During 2011-12 Dr. Seeto was on an expatriate assignment as the President of AstraZeneca Thailand, where he was the first MedImmune executive to participate in a talent exchange and development program with AstraZeneca. Under his leadership, Thailand achieved its sales targets for the first time in 5 years and was awarded the RVP Award for Leadership for management of the country's worst floods in more than half a century. Dr. Seeto originally joined MedImmune in 2008 as the Vice-President of Global Strategic Marketing and Portfolio Management where he worked closely with the R&D leadership team. He was later promoted to the MedImmune Executive Team (MET) and established the Corporate Development and Strategy Group. Prior to MedImmune, Dr. Seeto was Vice President of Global Marketing for Schering Plough/Organon Biosciences and Executive Director of US Marketing for Boehringer Ingelheim Pharmaceuticals. Earlier in his career he was a consultant at McKinsey & Company and started his career as a medical doctor involved in both clinical practice and research. He has also published first author publications in peer reviewed journals. Dr. Seeto holds his medical degree (with honors) from the University of Sydney, Australia.

tom street-PhotoAssistant Chief Administrative Officer, Montgomery County, Maryland

Thomas J. Street is currently serving as an Assistant Chief Administrative Officer for Montgomery County, Maryland. He is one of four such administrators within the County's management team, and supports and advises the Chief Administrative Officer in the areas of customer service, emergency response, re-development, and transportation. Mr. Street's areas of responsibility include oversight of the County's MC311 Initiative and coordinating issues such as Wheaton revitalization, inclement weather response, pedestrian safety, the Purple Line and Corridor Cities Transitway mass transit projects, and affordable housing .He has worked in Public Sector Financial Management for 29 years and in the Private Sector as an owner of an ecommerce company and partner in a financial advisory practice for six years. Tom began his career as Budget Analyst for Montgomery County, Maryland but spent the majority of his Public Sector career with the Washington Suburban Sanitary Commission (WSSC). While at WSSC, Tom was the Director of Budget and Financial Planning for 8 years, and the Chief of Strategic Planning and Business Development for 2 years.

Tom is a past president and board member of the Maryland-D.C. Utilities Association and has been a guest lecturer for the World Bank, Caribbean Development Bank, Maryland-China Business Council and U.S. Department of Environmental Protection. Mr. Street has a BA from The University of Florida and a Master's in Public Administration from The American University in Washington, D.C.